+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Waldenstroms macroglobulinemia with thalidomide

Treatment of Waldenstroms macroglobulinemia with thalidomide

Blood 96(11 Part 2): 286b, November 16

Thalidomide is an active agent in patients with refractory multiple myeloma. Based on these data we performed a phase II study in order to evaluate the activity of thalidomide in Waldenstrom's macroglobulinemia (WM). Thalidomide was administered on a dose-escalating schedule of 200 mg daily p.o. X 14 days with dose escalation by 200 mg every two weeks to a maximum dose of 600 mg. Twenty patients were treated with a median age of 74 years (range: 48 to 85 years). Hemoglobin was < 10.0 gr/dl in 5 patients, serum monoclonal IgM was >3.0 gr in 9 patients and lymphadenopathy and splenomegaly were present in 7 and 10 patients respectively. Ten patients were previously untreated, 1 was relapsing off treatment, 5 were primary refractory and 4 were treated during refractory relapse. Five patients (25%) achieved at least 50% reduction of serum monoclonal IgM and at least 50% reduction of tumor at all involved sites. At least 25% reduction of IgM was noted in all eventual responders within 4 weeks of thalidomide treatment. Responses occurred in 3 of 10 previously untreated patients and in 2 of 10 pretreated patients. One responding patient with artial fibrillation died of an embolic cerebral accident 4 months after achieving a response and the other responding patients remain without progression for 2+ months to 12+ months. Some degree of toxicity was observed in almost all patients. Grade 2 or 3 toxicities included constipation in 6 patients, somnolence in 3 patients, tremor in 2 patients and neuropathy in 2 patients. This explained the inability to reach the targeted dose of thalidomide 600 mg p.o. QD in all but 4 patients; the median daily dose of this agent was 200 mg. We conclude that thalidomide has moderate activity in WM. A relatively low median daily dose could be administered to this elderly patient population.

(PDF 0-2 workdays service: $29.90)

Accession: 035980650

Download citation: RISBibTeXText

Related references

Clarithromycin, Thalidomide and Dexamethasone for the Treatment of Waldenstroms Macroglobulinemia. Blood 100(11): Abstract No 5099, November 16, 2002

Immunomodulatory thalidomide derivatives have activity against tumor cells from Waldenstroms macroglobulinemia. Blood 102(11): 903a, November 16, 2003

Non-myelosuppressive therapy with BLT-D , low dose thalidomide and dexamethasone is highly active in Waldenstroms macroglobulinemia and myeloma. Blood 96(11 Part 1): 167a, November 16, 2000

Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Seminars in Oncology 30(2): 265-269, 2003

Waldenstroms macroglobulinemia Diagnosis and treatment. The Treatment Of Cancer With Special Reference To Radiotherapy And Chemotherapy: 57, 1965

Bcl-2 Antisense Treatment for Waldenstroms Macroglobulinemia. Blood 100(11): Abstract No 2275, November 16, 2002

Treatment of waldenstroms macroglobulinemia with alpha interferon. Journal of Clinical Pathology (London) 43(5): 437, 1990

Primary treatment of Waldenstroms macroglobulinemia with rituximab. Blood 98(11 Part 1): 367a, November 16, 2001

EBV-lymphoma after cladribine treatment for Waldenstroms macroglobulinemia. Blood 92(10 SUPPL 1 PART 1-2): 281B, Nov 15, 1998

Stem cell transplantation for treatment of Waldenstroms macroglobulinemia. Annals of Hematology 77(SUPPL 2): S183, 1998

Prospective evaluation of rituximab for the treatment of Waldenstroms macroglobulinemia. Blood 96(11 Part 1): 169a, November 16, 2000

Update of bolus administration of cladribine in the treatment of Waldenstroms macroglobulinemia. Blood 102(11): 402a, November 16, 2003

Recent advances in treatment of multiple myeloma and Waldenstroms macroglobulinemia. Biomedicine & Pharmacotherapy 55(9-10): 550-552, November, 2001

Abrupt IgM rise following treatment with rituximab in patients with Waldenstroms macroglobulinemia. Blood 98(11 Part 2): 240b-241b, November 16, 2001

Fludarabine, mitoxantrone and dexamethasone in the treatment of refractory Waldenstroms macroglobulinemia. Blood 90(10 SUPPL 1 PART 2): 308B-309B, Nov 15, 1997